Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TTK HEALTHCARE Mar-19 |
TEVA PHARMA Dec-13 |
TTK HEALTHCARE/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,215 | 2,950 | - | |
Low | Rs | 610 | 2,563 | - | |
Sales per share (Unadj.) | Rs | 444.4 | 1,693.2 | - | |
Earnings per share (Unadj.) | Rs | 17.2 | 105.8 | - | |
Cash flow per share (Unadj.) | Rs | 27.6 | 242.6 | - | |
Dividends per share (Unadj.) | Rs | 5.00 | 92.59 | - | |
Dividend yield (eoy) | % | 0.5 | 3.4 | 16.3% | |
Book value per share (Unadj.) | Rs | 177.9 | 1,880.8 | - | |
Shares outstanding (eoy) | m | 14.13 | 848.00 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.1 | 1.6 | 126.1% | |
Avg P/E ratio | x | 52.9 | 26.1 | 203.0% | |
P/CF ratio (eoy) | x | 33.0 | 11.4 | 290.7% | |
Price / Book Value ratio | x | 5.1 | 1.5 | 349.9% | |
Dividend payout | % | 29.0 | 87.5 | 33.1% | |
Avg Mkt Cap | Rs m | 12,894 | 2,337,529 | 0.6% | |
No. of employees | `000 | 2.3 | 44.9 | 5.1% | |
Total wages/salary | Rs m | 1,307 | 0 | - | |
Avg. sales/employee | Rs Th | 2,715.7 | 31,945.6 | 8.5% | |
Avg. wages/employee | Rs Th | 565.3 | 0 | - | |
Avg. net profit/employee | Rs Th | 105.4 | 1,995.6 | 5.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,279 | 1,435,794 | 0.4% | |
Other income | Rs m | 78 | 0 | - | |
Total revenues | Rs m | 6,356 | 1,435,794 | 0.4% | |
Gross profit | Rs m | 496 | 393,193 | 0.1% | |
Depreciation | Rs m | 147 | 116,057 | 0.1% | |
Interest | Rs m | 34 | 28,201 | 0.1% | |
Profit before tax | Rs m | 393 | 248,935 | 0.2% | |
Minority Interest | Rs m | 0 | 1,131 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -163,412 | 0.0% | |
Tax | Rs m | 149 | -3,039 | -4.9% | |
Profit after tax | Rs m | 244 | 89,693 | 0.3% | |
Gross profit margin | % | 7.9 | 27.4 | 28.8% | |
Effective tax rate | % | 37.9 | -1.2 | -3,106.5% | |
Net profit margin | % | 3.9 | 6.2 | 62.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,717 | 969,730 | 0.3% | |
Current liabilities | Rs m | 1,571 | 845,686 | 0.2% | |
Net working cap to sales | % | 18.3 | 8.6 | 211.3% | |
Current ratio | x | 1.7 | 1.1 | 150.9% | |
Inventory Days | Days | 32 | 91 | 35.4% | |
Debtors Days | Days | 47 | 96 | 48.6% | |
Net fixed assets | Rs m | 991 | 468,962 | 0.2% | |
Share capital | Rs m | 141 | 3,534 | 4.0% | |
Net worth | Rs m | 2,514 | 1,594,894 | 0.2% | |
Long term debt | Rs m | 3 | 734,153 | 0.0% | |
Total assets | Rs m | 4,158 | 3,281,248 | 0.1% | |
Interest coverage | x | 12.6 | 9.8 | 128.4% | |
Debt to equity ratio | x | 0 | 0.5 | 0.3% | |
Sales to assets ratio | x | 1.5 | 0.4 | 345.1% | |
Return on assets | % | 6.7 | 3.6 | 185.7% | |
Return on equity | % | 9.7 | 5.6 | 172.4% | |
Return on capital | % | 16.9 | 4.9 | 343.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 173 | 228,791 | 0.1% | |
From Investments | Rs m | 97 | -81,070 | -0.1% | |
From Financial Activity | Rs m | -307 | -274,450 | 0.1% | |
Net Cashflow | Rs m | -38 | -126,729 | 0.0% |
Compare TTK HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare TTK HEALTHCARE With: IPCA LABS ELDER PHARMA ALEMBIC PHARMA GLENMARK PHARMA NATCO PHARMA
| |
Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.
For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.
For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsWhat to do after every trade.
What we can learn from one of the greatest traders to have ever lived.
This corner of the market could provide more returns than blue chips in 2020.
Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
2019 will be remembered as the year of great money-making IPOs...
More
| |